ClinicalTrials.gg
RecruitingNCT07505186Updated Oct 2, 2026

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Camrelizumab and Esophagectomy in Esophageal Squamous Cell Carcinoma and Neoadjuvant Therapy, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 2, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma — 5 open to participants now, 7 under way, 2 of them phase 3. camrelizumab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
11th of 20
45 · median 46
Started
2026
with 2 others
Phase 2
13 of 20
2 open now
Registered
18th of 20
by date

Among the 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma, this one is the 11th largest by planned enrollment, is one of 3 that started in 2026, is one of 13 in phase 2, and was the 18th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

5 of the 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

In the management of locally advanced esophageal squamous cell carcinoma, the outcomes associated with surgical resection, whether conducted alone or supplemented with postoperative adjuvant radiotherapy and chemotherapy, have been suboptimal. Immune checkpoint inhibitors (ICIs) have shown potential in enhancing the immune system's capacity to target and eliminate cancer cells. Evidence suggests that the concurrent administration of JAK inhibitors with ICIs may improve anti-cancer efficacy, increase patient response rates, and prolong progression-free survival compared to ICIs alone. This prospective, exploratory study aims to assess the efficacy of combining camrelizumab, chemotherapy, and Ivarmacitinib in neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma, with the objective of broadening therapeutic options for this malignancy.

Read the detailed description

In the management of locally advanced esophageal squamous cell carcinoma, the outcomes associated with surgical resection, whether conducted alone or supplemented with postoperative adjuvant radiotherapy and chemotherapy, have been suboptimal. The high risk of local recurrence and distant metastasis, which affect patient prognosis and survival rates. Preoperative immunotherapy holds the potential to activate the patient's immune system to recognize tumor antigens and establish immune memory, thereby enabling the immune system to maintain its surveillance role following surgical tumor resection. Consequently, there is a growing emphasis on the administration of immunotherapy prior to surgery across various solid tumor types.

Immune checkpoint inhibitors (ICIs) have shown potential in enhancing the immune system's capacity to target and eliminate cancer cells. However, a substantial subset of patients either responds inadequately or develops resistance to these therapies. To address this challenge, numerous combination treatment strategies have been explored in clinical research. Evidence suggests that the concurrent administration of JAK inhibitors with ICIs may improve anti-cancer efficacy, increase patient response rates, and prolong progression-free survival compared to ICIs alone. Notably, there is a paucity of research regarding the combination of camrelizumab with chemotherapy and Ivarmacitinib as a neoadjuvant therapy. This prospective, exploratory study aims to assess the efficacy of combining camrelizumab, chemotherapy, and Ivarmacitinib in neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma, with the objective of broadening therapeutic options for this malignancy.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Therapy

Keywords

  • Camrelizumab
  • Ivarmacitinib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signed ;
  2. patients age 18 to 75 years old
  3. primary resectable, confirmed esophageal squamous cell cancer;
  4. Esophageal squamous cell carcinoma the clinical stage was II-IVA (according to AJCC TNM stage, 8th edition).
  5. PS 0-1.
  6. No distant , the diseases could be resectable assessed by thoracic oncologist.

Exclusion criteria

Exclusion Criteria:

  1. with significant cardiovascular disease;
  2. current treatment with anti-viral therapy or ;
  3. Female patients who are pregnant or lactating;
  4. history of within 5 years prior to screening;
  5. active or history of disease or immune deficiency;
  6. signs of distant .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Preoperative neoadjuvant treatment

    The preoperative neoadjuvant therapy consists of 3 cycles, each with a duration of 21 days. Ivarmacitinib tablets are administered orally at a dosage of 4 mg daily during the first and second cycles, but are omitted during the third cycle. Radical surgery is scheduled to occur between 4 to 8 weeks after the final dose of the neoadjuvant therapy. The requirement for postoperative radiotherapy is evaluated based on the patient's clinical condition and pathological stage. Camrelizumab maintenance therapy may be extended for up to 1 year. Throughout the study, patients are monitored until the occurrence of disease progression, withdrawal of informed consent, loss to follow-up, or death.

    Drug: Camrelizumab · Procedure: Esophagectomy · Other: Sample · Drug: Paclitaxel (albumin bound) · Drug: Carboplatin · Drug: Ivarmacitinib

Interventions

  • The treatment regimen includes the administration of Camrelizumab at a dose of 200 mg. These medications are administered every 3 weeks for a total of 3 cycles. Camrelizumab maintenance therapy may be extended for up to 1 year.

  • ProcedureEsophagectomy

    Prior to each surgical procedure, the department engaged in comprehensive discussions to determine and establish the most appropriate course of action. Depending on the tumor location, a minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two-field extensive lymphadenectomies, was performed. The resection length was required to be at least 5 cm from the tumor origin, as determined by pre-chemotherapy endoscopy. These surgeries were conducted by surgeons with extensive experience. Minimally invasive esophagectomy could be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or through an open approach, as deemed appropriate by the surgeon.

  • OtherSample

    Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and during surgery.

  • DrugPaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The treatment regimen includes the administration of Paclitaxel (albumin bound) at 260 mg/m². These medications are administered every 3 weeks for a total of 3 cycles.

  • The treatment regimen includes the administration of Carboplatin with an area under the curve (AUC) of 5. These medications are administered every 3 weeks for a total of 3 cycles.

  • Ivarmacitinib tablets are administered orally at a dosage of 4 mg daily during the first and second cycles, but are omitted during the third cycle, totaling 42 days of administration.

06

What researchers measure

Primary outcomes

  1. Pathological assessment: rate of pathological complete response (PCR)

    The proportion of the surgical population with PCR, which was defined no residual invasive tumor cells were found in the pathological examination of resected specimens, including the primary tumor and lymph nodes.

    Time frame: 1 month after surgery

Secondary outcomes

  1. Pathological assessment: rate of major pathological response (MPR)

    The proportion of the surgical population with MPR, which was defined in the pathological examination of resected specimens, the proportion of residual tumor cells was less than ten percent.

    Time frame: 1 month after surgery

  2. Imaging assessment: rate of objective response rate (ORR)

    The proportion of subjects with imaging PR or CR assessed according to RECIST 1.1 criteria

    Time frame: before surgery]

  3. 2-year and 5-year event free survival (EFS)

    The proportion of study cases from the time of enrollment to either the occurrence of disease recurrence or death from any cause, whichever occurred first, was analyzed within both 2-year and 5-year intervals.

    Time frame: 2-year and 5-year after enrolled

  4. Incidence of Treatment-related Adverse Events

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 1 month after surgery

  5. The changes in the peripheral blood immunoprofile and tumor tissue sample among non-PCR (NPCR) and PCR patients

    By using mass spectrometry (CyTOF), single-cell analysis, and other detecting techniques , we comprehensively characterized the immune landscape in the peripheral blood and tumor sample of ESCC patients before and after anti- PD-1 immunotherapy, aiming to explore the immune subsets correlated with neoadjuvant immunotherapy response.

    Time frame: 3 month after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 28 months is below that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Aug 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 1, 2026
StartActual
Aug 17, 2026was May 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2033
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
2nd Affiliated Hospital, School of Medicine, Zhejiang University is now Recruiting
Oct 2, 2026
Start date
May 1, 2026→Aug 17, 2026 (actual)
Oct 2, 2026
Interventions
Added Drug: Camrelizumab·Drug: Paclitaxel (albumin bound)·Drug: Carboplatin·Drug: Ivarmacitinib; removed Combination product: Camrelizumab, Chemotherapy and Ivarmacitinib. Arm changed Camrelizumab, Chemotherapy and Ivarmacitinib→Preoperative neoadjuvant treatment
Oct 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRatePathological assessment: rate of pathological complete response (PCR)Time frame: 1 month after surgery
Oct 2, 2026
Secondary outcomes
2 edited, 1 description edited
What changed in the outcomes
  • EditedRatePathological assessment: rate of major pathological response (MPR)Time frame: 1 month after surgery
  • EditedRateImaging assessment: rate of objective response rate (ORR)Time frame: before surgery]
  • DescriptionIncidence of Treatment-related Adverse Events: how it is measured was reworded
Oct 2, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    2nd Affiliated Hospital, School of Medicine, Zhejiang University is now Recruiting
    Start date May 1, 2026→Aug 17, 2026 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRatePathological assessment: rate of pathological complete response (PCR)Time frame: 1 month after surgery
    Secondary outcomes 2 edited, 1 description edited
    What changed in the outcomes
    • EditedRatePathological assessment: rate of major pathological response (MPR)Time frame: 1 month after surgery
    • EditedRateImaging assessment: rate of objective response rate (ORR)Time frame: before surgery]
    • DescriptionIncidence of Treatment-related Adverse Events: how it is measured was reworded
    Interventions Added Drug: Camrelizumab·Drug: Paclitaxel (albumin bound)·Drug: Carboplatin·Drug: Ivarmacitinib; removed Combination product: Camrelizumab, Chemotherapy and Ivarmacitinib. Arm changed Camrelizumab, Chemotherapy and Ivarmacitinib→Preoperative neoadjuvant treatment
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 2 other changes: index terms and identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07505186
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Aug 17, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Oct 2, 2026

Study contacts

Zixiang Wu, M.D
Contact
zixiang0717@zju.edu.cn
+8615268156132
Jianan Wang
study chair · 2nd Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Ivarmacitinib

Start the discussion